Clinical Trial Update: Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating emend (aprepitant) to prevent delayed emesis in breast cancer patients receiving cyclophosphamide plus anthracycline chemotherapy; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• EMEND (aprepitant)

Snippet

Sponsor: S. Maria Hospital, Terni | Conditions: Emesis | Phase 3 | Status: TERMINATED